Evidence Hub

Is Standard Oral Dose Dexamethasone (6mg Once Daily) Prescribed For COVID-19 Pneumonitis Treating Autoimmune Haemolytic Anaemia Associated with COVID-19? A Case Series of Five Patients Providing Us with the Answer

S. Siddiqui

International Journal of Innovative Research in Medical Science, 2021

1 citation

Abstract

Initially originating as an epidemic respiratory illness in Wuhan, China, COVID-19 eventually spread around the world and has now been declared as a global pandemic disease by the WHO. Our understanding of the pathophysiology of SARS-CoV-2 is evolving with each passage of days. Previously thought to be a respiratory illness resulting in pulmonary complications such as pneumonia, respiratory failure, and acute respiratory distress syndrome now have been found to be causing multiple extra-pulmonary pathologies which includes various degree of autoimmune disorders. Certain group of patients have been found to have autoimmune haemolytic anaemia triggered by COVID-19. We report a case series of five patients who developed COVID-19 induced AIHA which responded dramatically to oral dexamethasone (6mg once daily) initially prescribed for the deteriorating pulmonary function. Therefore, our intuition is dexamethasone prescribed for COVID-19 pneumonitis is beneficial for the rapid recovery of AIHA associated with COVID-19.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free